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BACKGROUND
The Early Treatment Diabetic Retinopathy Study [1] (ETDRS) showed
that focal photocoagulation of “clinically significant” diabetic
macular oedema (CSMO) substantially reduced the risk of visual
loss. Vascular Endothelial Growth Factor (VEGF) inhibitor drugs have
subsequently been shown to have better results for centre involving
diabetic macular oedema [2].
METHODS
A retrospective analysis of first macular laser treatment was conducted
between 01/01/2010 and 31/12/2019 and OCT measurements from the
same machine, within 3 months before and 1–12 months after treatment
in the Gloucestershire Eye Unit. Eyes were excluded if their central subfield
retinal thickness (CRT) was ≥ 400 microns, they had ocular co-pathologies
or surgery in the previous 6 months. ETDRS grid areas described by
Soliman [3] were used to assess the results of laser treatment (Fig. 1).
RESULTS
Eligible for analysis were 316 eyes from 275 patients with 175
male, 246 T2DM, and median age 63.1 years. A total of 8
consultants treated 198 (62.7%) eyes, 5 specialty doctors treated
101 (32.0%) eyes and 11 trainees treated 17 (5.4%) eyes with 2
consultants treating >50 eyes. The laser machine used was a
PASCAL green laser (Topcon UK) for 271 (85.8%) eyes. The median
number of burns administered to an eye was 24 (IQR; 15–34). Burn
durations of 0.02 or 0.05 s were used for 69.3% of eyes. For 311
(98.4%) eyes the beam diameter was 100 microns.
A total of 253 eyes had Zeiss Cirrus OCT measurements
(Table 1), mean baseline CRT 303.6 microns, mean follow-up CRT
305.1 microns and mean difference +1.5 microns (95% CI: −4.8
to +7.7). In only two macular regions did <50% of eyes have a
reduction in thickness. A total of 63 eyes had Heidelberg
OCT measurements, mean baseline CRT 302.4 microns, mean
follow-up CRT 309.4 microns and mean difference +7.0 microns
(95% CI: −4.7 to +18.8). In all macular regions >50% of eyes had
a reduction in thickness.
After VEGF inhibitor injections became available in 2013, only 3
(5.4%) eyes with Heidelberg and 10 (10.5%) eyes with Zeiss OCT
measurements received injections within 1 year of laser.
The median baseline and follow up Visual Acuity (VA) were both
0.20 LogMAR.
DISCUSSION
The Diabetic Retinopathy Clinical Research Network (DRCRN) [4]
compared two laser techniques in 2007 that had OCT data available
on 213 eyes at 12 months post laser. They found, in both treatment
groups, a reduction of central retinal thickening, weighted inner
zone thickening, and retinal volume with no significant change in
visual acuity outcomes.
As the NICE guidelines [5] in England do not recommend
treatment until the central subfield retinal thickness (CRT) is ≥400
microns, macular laser treatment was assessed for predominantly
non-centre involving diabetic macular oedema.
Macular laser treatment can be effective in reducing retinal
thickening in the inner and outer parafoveal zones and in different
macular regions with stable VA. Only 5.1% of eyes went on to
Fig. 1 Early treatment diabetic retinopathy study (ETDRS) grid
areas. ETDRS grid right eye, ETDRS grid left eye, ETDRS central 1 mm,
inner and outer parafoveal rings both eyes.
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require injections with VEGF inhibitors within 12 months of the
initial laser. This study provides evidence that there is still a place
for macular laser treatment in non-centre involving diabetic
macular oedema.
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